Patients with pulmonary arterial hypertension (PAH) had similar efficacy and safety profile when taking either oral Treprostinil or selexipag, indicating that Treprostinil would be an adequate replacement.
Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.
This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.